HPGC Renmintongtai Pharmaceutical Corporation

Equities

600829

CNE000000G05

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
6.45 CNY +0.78% Intraday chart for HPGC Renmintongtai Pharmaceutical Corporation +3.86% -17.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HPGC Renmintongtai Chairman Steps Down; Successor Named MT
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2022 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2019 CI
HPGC Renmintongtai Pharmaceutical Corporation Approves Amending of Articles of Association CI
HPGC Renmintongtai Pharmaceutical Corporation announced that it has received funding from Harbin Pharmaceutical Group Co., Ltd. CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2019 CI
Harbin Pharmaceutical Group Holding Co., Ltd. made an offer to acquire minority stake in HPGC Renmintongtai Pharmaceutical Corporation for CNY 0.02 million. CI
Harbin Pharmaceutical Group Holding Co., Ltd. made an offer to acquire 25.2% stake in HPGC Renmintongtai Pharmaceutical Corporation for approximately CNY 970 million. CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2019 CI
HPGC Renmintongtai Pharmaceutical Corporation announced that it expects to receive funding from Harbin Pharmaceutical Group Co., Ltd. CI
Chart HPGC Renmintongtai Pharmaceutical Corporation
More charts
HPGC Renmintongtai Pharmaceutical Corporation, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd., is a China-based company, principally engaged in the wholesale and retail of pharmaceuticals. The Company principally engages in the sales of Chinese medicines and western drugs. It also engages in the sales of medical equipment, healthcare products, daily necessities, glass apparatus, chemical, among others. The Company distributes its products mainly within domestic markets.
More about the company